Global Neuroimmunology Drugs Market

Report ID : 1171 | Published : 2022-08-16 | Pages: 140 | Format: PDF/EXCEL

Neuroimmunology includes applied and fundamental biology, immunology, neurology, chemistry, pathology, virology, and psychiatry of the central nervous system (CNS). The study of communications of the nervous system and immune is known as neuroimmunology. The development of the drug in neuroimmunology is anticipated to witness robust growth in the global market. The advancements in neurogenetics, fundamental pathology of the numerous diseases, and targeted therapy mechanism for drug development are some of the key factors boosting the neuroimmunology drugs market globally.  The neuroimmunology drug market size is expected to reach US$ 37.32 Billion by 2030, growing at a CAGR of 6.93% over the forecast period of 2022-2030. The presence of a large number of drugs in clinical stages for the treatment of neuroimmunology diseases such as Multiple Sclerosis (MS), and Alzheimer’s disease (AD) is expected to generate immense opportunity for the market in the coming years. Additionally, numerous strategies opted by companies to develop advanced treatment options such as studying different targets for drug acting.

Small molecule and mAbs are the most common type of molecule in neuroimmunology, as they penetrate the blood-brain barrier. The high prevalence of neuroimmunology disease globally is expected to boost the demand for the drugs market in the coming years. According to the National MS Society, in 2019 about one million people living in the U.S. were suffering from multiple sclerosis. The number is twice of people suffering in 1975. The growing prevalence of neuroimmunology diseases is expected to generate substantial demand for advanced treatment options globally. However, the high cost associated with mAbs based therapy may hinder market growth significantly. However, research and development activities among research universities, hospitals, and companies operating in the market are projected to generate immense opportunities for the growth of the market globally.

The Global Neuroimmunology Drugs Market is segmented on the basis of indication, target type, and region. Based on the indication, the neuroimmunology drugs market is divided into Multiple Sclerosis (MS), Alzheimer’s disease (AD), and Others. The wide range of pipeline drugs for these indications are expected to boost the segmental growth during the estimated timeframe. The market is segmented into Cytokines, Lymphocytes or Molecules Associated with their Activation or Migration, and Others based on target type. The cytokines is the most common receptor for pipeline drugs of multiple sclerosis. About 35% of pipeline drugs for MS are targeting cytokine receptors. On the basis of the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. The Asia Pacific is estimated to register high growth in the neuroimmunology drugs market during the estimated timeframe.

The key players of this market include F. Hoffmann-La Roche Ltd, Biogen, AstraZeneca Plc, T3D Therapeutics, Johnson & Johnson, Merck KGaA, Celgene Corp., Novartis AG, Sanofi, UCB SA, Eisai Co Ltd, Eli Lilly, Tiaki Therapeutics, AB Science S.A., ImmunoBrain Checkpoint, Actelion Pharmaceuticals Ltd., AstronauTx, Alector, AZTherapies Inc., INmune Bio, Inc., Lundbeck, Genetech Inc., Grifols SA, T.G. Therapeutics Inc., Talisman Therapeutics, AevisBio Inc., Monument Tx, Inflammasome Therapeutics, and TauRX Therapeutics Ltd among others.


Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Neuroimmunology Drugs Market Snapshot

Chapter 4. Global Neuroimmunology Drugs Market Variables, Trends & Scope

4.1. Market Segmentation & Scope 

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Clinical Trial/Pipeline Analysis 2021

4.6. Industry Analysis – Porter’s Five Forces Analysis 

4.7. Technology Advancement in Neuroimmunology Drugs 

4.8. Impact of COVID 19 on Pharmaceutical Industry

Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis

5.1. Indication Type & Market Share, 2021 & 2030

5.2.  Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2030 for the following Indication:

5.2.1. Alzheimer’s disease (AD)

5.2.2. Multiple Sclerosis (MS)

5.2.3. Parkinson's Disease (P.D.)

5.2.4. Myasthenia Gravis (M.G.)

5.2.5. Neuromyelitis Optica Spectrum Disorder (NMOSD)

5.2.6. Guillain-Barre Syndrome (GBS)

5.2.7. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

5.2.8. Amyotrophic Lateral Sclerosis (ALS)

5.2.9. Others

Chapter 6.  Neuroimmunology Drugs Market Segmentation 2: Product Type Estimates & Trend Analysis

6.1. Product Type Analysis & Market Share, 2021 & 2030

6.2.  Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2030 for the following Product Type:

6.2.1. Small Molecules

6.2.2. Monoclonal Antibodies

6.2.3. Recombinant Protein

6.2.4. Others

Chapter 7.  Neuroimmunology Drugs Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America 

7.1.1. North America Neuroimmunology Drugs Market revenue (US$ Million) estimates and forecasts by Indication, 2019-2030

7.1.2. North America Neuroimmunology Drugs Market revenue (US$ Million) estimates and forecasts by Product Type, 2019-2030

7.1.3. North America Neuroimmunology Drugs Market revenue (US$ Million) estimates and forecasts by country, 2019-2030 U.S. Canada

7.2. Europe

7.2.1. Europe Neuroimmunology Drugs Market revenue (US$ Million) by Indication, 2019-2030

7.2.2. Europe Neuroimmunology Drugs Market revenue (US$ Million) by Product Type, 2019-2030

7.2.3. Europe Neuroimmunology Drugs Market revenue (US$ Million) by country, 2019-2030 Germany France UK Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific Neuroimmunology Drugs Market revenue (US$ Million) by Indication, 2019-2030

7.3.2. Asia Pacific Neuroimmunology Drugs Market revenue (US$ Million) by Product Type, 2019-2030

7.3.3. Asia Pacific Neuroimmunology Drugs Market revenue (US$ Million) by country2019-2030 China Japan Australia Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America Neuroimmunology Drugs Market revenue (US$ Million) by Indication, 2019-2030

7.4.2. Latin America Neuroimmunology Drugs Market revenue (US$ Million) by Product Type, 2019-2030

7.5. MEA

7.5.1. MEA revenue Neuroimmunology Drugs Market revenue (US$ Million) by Indication, 2019-2030

7.5.2. MEA Neuroimmunology Drugs Market revenue (US$ Million) by Product Type, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. F. Hoffmann-La Roche Ltd

8.2.2. Biogen

8.2.3. AstraZeneca Plc

8.2.4. Johnson & Johnson

8.2.5. Merck KGaA

8.2.6. Novartis AG

8.2.7. Sanofi

8.2.8. UCB SA

8.2.9. Eisai Co Ltd

8.2.10. Eli Lilly

8.2.11. Actelion Pharmaceuticals Ltd.

8.2.12. AstronauTx

8.2.13. Alector

8.2.14. AZTherapies Inc.

8.2.15. Celgene Corp.

8.2.16. INmune Bio, Inc.

8.2.17. Lundbeck

8.2.18. Genetech Inc.

8.2.19. Grifols SA

8.2.20. Tiaki Therapeutics

8.2.21. T.G. Therapeutics Inc.

8.2.22. TauRX Therapeutics Ltd

8.2.23. AB Science S.A.

8.2.24. ImmunoBrain Checkpoint

8.2.25. Talisman Therapeutics

8.2.26. Inflammasome Therapeutics

8.2.27. T3D Therapeutics

8.2.28. Other Prominent Players

Global Neuroimmunology Drugs Market Segmentation:

Global Neuroimmunology Drugs Market by IndicationAlzheimer's disease (A.D.)

  • Multiple Sclerosis (M.S.)
  • Parkinson's Disease (P.D.)
  • Myasthenia Gravis (M.G.)
  • Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Guillain-Barre Syndrome (GBS)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Others


Global Neuroimmunology Drugs Market Based on Product Type

  • Small Molecules
  • Monoclonal Antibodies
  • Recombinant Protein
  • Others

Global Neuroimmunology Drugs Market Based on Region


  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America

  • U.S.
  • Canada

Asia Pacific

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..